Skip to main content
Many Bright Ideas Technologies Inc. logo

Many Bright Ideas Technologies Inc. — Investor Relations & Filings

Ticker · MBI.H ISIN · CA5650851077 TSXV Professional, scientific and technical activities
Open in API
Filings indexed 261 across all filing types
Latest filing 2022-04-09 AGM Information
Country CA Canada
Listing TSXV MBI.H

About Many Bright Ideas Technologies Inc.

https://www.medbiogene.com/

Many Bright Ideas Technologies Inc. is a technology commercialization company focused on the acquisition, development, and commercialization of intellectual property across various industrial sectors, emphasizing alternative non-medical technologies. The company maintains a significant legacy interest in the life sciences domain. Its primary licensed asset is GeneFx® Lung, a proprietary gene expression-based diagnostic test. GeneFx® Lung is designed to assist in personalized treatment decisions for patients with early-stage non-small-cell lung cancer (NSCLC) by predicting mortality risk and identifying those who may benefit from adjuvant chemotherapy. Exclusive global rights for the development and commercialization of GeneFx® Lung are held by Precision Therapeutics, Inc.

Recent filings

Filing Released Lang Actions
Management information circular - English.pdf
AGM Information Classification · 95% confidence The document is a Notice of Annual General Meeting (AGM) and an Information Circular for Med BioGene Inc. It includes details about the AGM date, location, agenda items such as election of directors and appointment of auditors, proxy solicitation instructions, voting procedures, and shareholder information. It also mentions that the financial statements and auditor's report for the year ended December 31, 2020, will be presented at the meeting, but these statements are not included in the document itself. The document is primarily intended to inform shareholders about the AGM and solicit their proxies for voting. This matches the definition of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting. The document is lengthy (15,000 characters) and contains detailed proxy and meeting information, consistent with an AGM Information filing rather than a simple announcement or proxy solicitation only. Therefore, the correct classification is AGM-R with high confidence.
2022-04-09 English
Other.pdf
Regulatory Filings Classification · 95% confidence The document is a short form (1121 characters) that is a request form for shareholders to receive Interim Financial Statements and/or Annual Financial Statements by mail. It does not contain any actual financial data or analysis, nor does it present any report itself. It is essentially a mailing list request form related to financial reports. According to the MENU VS MEAL RULE, this is an announcement or request related to reports, not the reports themselves. Therefore, it should be classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other categories.
2022-04-09 English
Notice of the meeting and record date - English.pdf
AGM Information Classification · 95% confidence The document is a notification to Canadian Securities Regulatory Authorities about an upcoming Annual General Meeting (AGM) for Med Biogene Inc. It provides details such as meeting type, record dates, meeting date, location, and proxy material handling. The document does not contain any financial data, results, or detailed reports but rather logistical information about the AGM. The length is short (1012 characters), and it is clearly an announcement related to the AGM rather than the AGM materials themselves. Therefore, it fits best under AGM Information (AGM-R).
2022-03-04 English
News release - English.PDF
Capital/Financing Update Classification · 95% confidence The document is a news release announcing the closing of a shares for debt transaction involving the issuance of common shares to settle indebtedness. It includes details about the transaction, related party considerations under Multilateral Instrument 61-101, and early warning disclosure about share ownership changes by a director. There are no financial statements or comprehensive financial data presented, nor is this a report or presentation. The content focuses on a capital transaction and share issuance related to settling debt. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length is 4475 characters, which is sufficient for a detailed announcement but not a full report. Confidence is high given the clear focus on a financing transaction and share issuance.
2022-02-15 English
News release - English.pdf
Capital/Financing Update Classification · 100% confidence The document is a news release announcing a shares-for-debt transaction where the company will issue shares to settle indebtedness. It mentions the transaction details, related party nature, and regulatory approval requirements. There is no financial report, earnings data, or detailed financial statements. The document is an announcement of a capital transaction involving share issuance, which fits the Capital/Financing Update category. The document length is short and it is not a report publication or certification. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2022-02-03 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings
2021-11-26 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.